Dejerine–Sottas disease
Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD medical weight loss NYC and sleep center NYC
Dejerine–Sottas disease | |
---|---|
![]() | |
Synonyms | Hereditary motor and sensory neuropathy type III, Hypertrophic interstitial neuropathy of infancy |
Pronounce | |
Specialty | Neurology |
Symptoms | Muscle weakness, sensory loss, areflexia, foot deformities |
Complications | N/A |
Onset | Infancy or early childhood |
Duration | Chronic |
Types | N/A |
Causes | Genetic mutation |
Risks | |
Diagnosis | Clinical examination, nerve conduction study, genetic testing |
Differential diagnosis | Charcot-Marie-Tooth disease, Friedreich's ataxia |
Prevention | N/A |
Treatment | Physical therapy, orthopedic surgery, supportive care |
Medication | N/A |
Prognosis | Variable, often progressive |
Frequency | Rare |
Deaths | N/A |
Dejerine–Sottas disease (DSD), also known as hereditary motor and sensory neuropathy type III (HMSN III) or Dejerine–Sottas neuropathy, is a rare genetic disorder that affects the peripheral nervous system. It is characterized by progressive muscle weakness and sensory loss, primarily in the extremities.
History
Dejerine–Sottas disease was first described by Joseph Jules Dejerine and Jules Sottas in 1893. The condition is named after these two French neurologists who identified the disease based on its clinical and pathological features.
Genetics
Dejerine–Sottas disease is typically inherited in an autosomal recessive manner, although some cases may follow an autosomal dominant pattern. Mutations in several genes, including PMP22, MPZ, EGR2, and PRX, have been associated with the disease. These genes are involved in the development and maintenance of myelin, the protective sheath surrounding nerve fibers.
Pathophysiology
The primary pathological feature of Dejerine–Sottas disease is the abnormal development and maintenance of myelin, leading to demyelination and subsequent axonal loss. This results in impaired nerve conduction and the clinical manifestations of the disease.
Clinical Features
Patients with Dejerine–Sottas disease typically present in early childhood with symptoms such as:
- Progressive muscle weakness, particularly in the legs and feet
- Loss of sensation in the extremities
- Areflexia (absence of reflexes)
- Foot deformities such as pes cavus (high-arched feet)
- Scoliosis (curvature of the spine)
Diagnosis
The diagnosis of Dejerine–Sottas disease is based on clinical evaluation, family history, and genetic testing. Nerve conduction studies and electromyography (EMG) can help assess the extent of nerve damage. Nerve biopsy may show characteristic features such as onion bulb formations due to repeated cycles of demyelination and remyelination.
Treatment
There is currently no cure for Dejerine–Sottas disease. Treatment is primarily supportive and focuses on managing symptoms and improving quality of life. This may include:
- Physical therapy to maintain muscle strength and mobility
- Orthopedic devices such as braces or orthotics to support weakened limbs
- Pain management for neuropathic pain
- Surgical interventions for severe foot deformities or scoliosis
Prognosis
The progression of Dejerine–Sottas disease varies among individuals. Some patients may experience a relatively mild course, while others may develop significant disability. Early intervention and supportive care can help manage symptoms and improve outcomes.
See also
See Also
References
External Links
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD